Cumberland Emerging Technologies, Inc. (CET) today announced that InvisionHeart, Inc. has established operations at the CET Life Sciences Center. The Life Sciences Center, which is located in downtown Nashville, provides lab and office space, equipment and infrastructure to early-stage biomedical ventures.
InvisionHeart has developed a device that allows health care providers to read and transmit real-time electrocardiogram (ECG) tracings directly to cardiologists via smartphones and tablets. Through a HIPAA compliant cloud platform, health care professionals with a credentialed mobile device can instantly access captured ECG tracings, as well as select alerts and push notifications to aid in the swift treatment of patients.
InvisionHeart is a 2014 recipient of the NEXT Award for healthcare startups. The NEXT Awards, hosted by the Nashville Area Chamber of Commerce and the Nashville Entrepreneur Center, honor Nashville’s fast-growing, innovative companies and leading entrepreneurs.
“We are delighted to join the community of companies at the CET Life Sciences Center,” said Josh Nickols, President and CEO of InvisionHeart. “Our office is a great fit for the needs of a collaborative, team-oriented layout, as well as being suited to the requirements of a controlled manufacturing location. The center is conveniently located near the resources of Vanderbilt University, the Nashville Entrepreneur Center, and other healthcare companies that have supported development of the InvisionHeart ECG technology. This location and the second half of 2015 will be vitally important as we prepare for the introduction of our products to the market.”
“We are very pleased to welcome InvisionHeart to the growing community of healthcare entrepreneurs at the CET Life Sciences Center,” said A.J. Kazimi, Chief Executive Officer of CET and Cumberland Pharmaceuticals. “We are committed to helping build the biomedical segment of the healthcare industry in Middle Tennessee.”
About Cumberland Emerging Technologies:
Cumberland Emerging Technologies, Inc. (www.cet-fund.com) is a joint initiative between Cumberland Pharmaceuticals Inc., Vanderbilt University, LaunchTN, and Gloria Pharmaceuticals. The mission of CET is to bring biomedical technologies and products conceived at Vanderbilt and other regional research centers to the marketplace. CET helps manage the development and commercialization process for select projects, and provides expertise on intellectual property, regulatory, manufacturing and marketing issues that are critical to successful new biomedical products. CET’s Life Sciences Center, located in Nashville, Tennessee, provides laboratory space, equipment and infrastructure to early-stage life sciences companies.